Several points summarized above, namely (a) the strong functional link between DLG2 and NMDA glutamate receptors [14], (b) the role of DLG2 in associative learning [17,19], (c) the association of DLG2 with cognitive and neurodevelopmental disorders [21,22,23,24,25,26,27,28,29], and (d) the decreasing memory performance observed in our patient at early adolescence, when the brain physiologically undergoes a massive pruning of glutamatergic synapses [31], all led to the suggestion that therapies able to boost NMDA receptor function might have been beneficial to our patient. The gene discussed is DLG2; the disease is neurodevelopmental disorder.